Avalo Therapeutics, Inc.

Ownership Transactions Reported by 25 Insiders

Symbol
AVTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
540 Gaither Road, Suite 400, Rockville, MD

Insiders trading volume in the past year

Avalo Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Garry Arthur Neil Chief Executive Officer $2.09M Mar 28, 2025
Christopher Ryan Sullivan Chief Financial Officer $553K Mar 28, 2025
Armistice Capital, Llc 10%+ Owner $398K Jun 26, 2023
June Almenoff Director $88.8K +$12.8K +16.8% Mar 28, 2025
Aaron Kantoff Director $80.4K Mar 28, 2025
Jonathan Goldman Director $80.4K Mar 28, 2025
Samantha Truex Director $80.4K Mar 28, 2025
Mitchell Chan Director $80.4K Mar 28, 2025
Gilla Kaplan Director $80.4K Mar 28, 2025
James Archie Harrell Jr Chief Commercial Officer $19.1K Dec 10, 2021
H. Jeffrey Wilkins Chief Medical Officer $17.3K Dec 10, 2021
Schond Greenway Cfo $2.02K Dec 10, 2021
Stephen Smolinski Chief Commercial Officer Jan 4, 2022
Mittie Doyle Chief Medical Officer Jan 28, 2025
Jennifer Riley Chief Strategy Officer Jan 1, 2025
Michael Thomas Heffernan Director Mar 25, 2025
Michael F. Cola Chief Executive Officer, Director Oct 1, 2021
Suzanne Louise Bruhn Director Nov 10, 2021
Joseph M. Miller Director Mar 31, 2022
Magnus Persson Director Dec 20, 2023
Caissa Capital Management ltd. 10%+ Owner Jun 26, 2023
Paul Varki Chief Legal Officer Jan 28, 2025
Phil Gutry Director Dec 1, 2021
Illya Keith Maher Director Oct 15, 2021
Sol J. Barer Director Jun 15, 2021

Recent Insider Transactions by Companies or Individuals for Avalo Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.